-Z M Ruggeri Researcher Activity Profile

Research Author Detailed Information 

Z M Ruggeri Publication Rate By Year

Z M Ruggeri has published 1 paper(s) in 1990, 2 paper(s) in 1991, 1 paper(s) in 1992, 7 paper(s) in 1993, 2 paper(s) in 1996, 2 paper(s) in 1997, 2 paper(s) in 1998, 1 paper(s) in 1999, 2 paper(s) in 2000, 2 paper(s) in 2003, 1 paper(s) in 2004, 5 paper(s) in 2006, 9 paper(s) in 2007, 8 paper(s) in 2008, for a total of 45 research publications in total.

Z M Zm Ruggeri Author Information

LAST NAME: ruggeri

FIRST NAME: Z M

INITIALS: zm

AFFILIATION:

Papers

Z M Ruggeri's Publication Record

1. Distinct antithrombotic consequences of platelet glycoprotein Ibalpha and VI deficiency in a mouse model of arterial thrombosis. Year Published: 2006
Department of Molecular and Experimental Medicine, Division of Experimental Hemostasis and Thrombosis, The Roon Center for Arteriosclerosis and Thrombosis, The Scripps Research Institute, La Jolla, CA, USA.
2. The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Year Published: 2006
CBR Institute for Biomedical Research and Department of Pathology, Harvard Medical School, Boston, MA 02115, USA. bergmeier@cbrinstitute.org
3. ADAP is required for normal alphaIIbbeta3 activation by VWF/GP Ib-IX-V and other agonists. Year Published: 2007
Department of Medicine, University of California San Diego, La Jolla 92093-0726, USA. akasirer@ucsd.edu
4. HBV pathogenesis in animal models: recent advances on the role of platelets. Year Published: 2007
Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037, USA.
5. Altered von Willebrand factor subunit proteolysis and multimer processing associated with the Cys2362Phe mutation in the B2 domain. Year Published: 2007
Dept of Medical and Surgical Sciences, via Ospedale Civile 105, Padova, Italy. sandra.casonato@unipd.it
6. The role of von Willebrand factor in thrombus formation. Year Published: 2007
The Scripps Research Institute, La Jolla, California, USA. Ruggeri@scripps.edu
7. Antiplatelet drug therapy moderates immune-mediated liver disease and inhibits viral clearance in mice infected with a replication-deficient adenovirus. Year Published: 2007
Department of Molecular and Experimental Medicine, Scripps Research Institute, 10550 North Torrey Pines Rd., La Jolla, CA 92037, USA.
8. Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. Year Published: 2007
Department of Medicine, University of California, San Diego, La Jolla, CA 92093.
9. Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. Year Published: 2007
Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
10. Platelets prevent IFN-{alpha}/ -induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. Year Published: 2008
Departments of Molecular and Experimental Medicine and Molecular and Integrative Neurosciences, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037.
11. Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. Year Published: 2007
Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
12. Antiplatelet drug therapy moderates immune-mediated liver disease and inhibits viral clearance in mice infected with a replication-deficient adenovirus. Year Published: 2007
Department of Molecular and Experimental Medicine, Scripps Research Institute, 10550 North Torrey Pines Rd., La Jolla, CA 92037, USA.
13. Platelets prevent IFN-{alpha}/ -induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. Year Published: 2008
Departments of Molecular and Experimental Medicine and Molecular and Integrative Neurosciences, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037.
14. Platelets prevent IFN-alpha/beta-induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. Year Published: 2008
Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.
15. The Modifier of hemostasis (Mh) locus on chromosome 4 controls in vivo hemostasis of Gp6-/- mice. Year Published: 2008
16. Platelets prevent IFN-alpha/beta-induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. Year Published: 2008
Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.
17. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Year Published: 2000
Roon Research Center for Arteriosclerosis and Thrombosis, Division of Experimental Hemostasis and Thrombosis, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA. jware@scripps.edu
18. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Year Published: 2000
Center for Blood Research and the Department of Pathology, Harvard Medical School, Boston, MA, USA.
19. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Year Published: 2003
A. Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine, Istituto di Ricovero e Cura a Carattere Scientifico-Ospedale Maggiore, University of Milan, 20122 Milan, Italy. marco.cattaneo@unimi.it
20. The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Year Published: 2003
Roon Research Center for Arteriosclerosis and Thrombosis, Division of Experimental Hemostasis and Thrombosis, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA.
21. A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ibalpha for the diagnosis of patients with low von Willebrand factor levels. Year Published: 2004
Angelo Bianchi Bonomi Hemophilia Thrombosis Center, Department of Internal Medicine and Dermatology, IRCCS Maggiore Hospital and University of Milan, Italy. augusto.federici@unimi.it
22. Nonsense mutation in the glycoprotein Ib alpha coding sequence associated with Bernard-Soulier syndrome. Year Published: 1990
Roon Research Center for Cardiovascular Disease and Thrombosis, Department of Molecular and Experimental Medicine, Research Institute of Scripps Clinic, La Jolla, CA 92037.
23. Identification of a point mutation in type IIB von Willebrand disease illustrating the regulation of von Willebrand factor affinity for the platelet membrane glycoprotein Ib-IX receptor. Year Published: 1991
Roon Research Laboratory for Arteriosclerosis and Thrombosis, Department of Molecular and Experimental Medicine, Research Institute of Scripps Clinic, La Jolla, CA 92037.
24. Site-directed mutagenesis of a soluble recombinant fragment of platelet glycoprotein Ib alpha demonstrating negatively charged residues involved in von Willebrand factor binding. Year Published: 1991
Department of Molecular and Experimental Medicine, Scripps Clinic and Research Foundation, La Jolla, California 92037.
25. The structure and function of von Willebrand factor. Year Published: 1992
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, CA 92037.
26. Disulfide bond requirements for assembly of the platelet glycoprotein Ib-binding domain of von Willebrand factor. Year Published: 1993
Roon Research Laboratory for Arteriosclerosis and Thrombosis, Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.
27. von Willebrand factor. Year Published: 1993
Roon Research Laboratory for Arteriosclerosis and Thrombosis, Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.
28. A role for von Willebrand factor proline residues 702-704 in ristocetin-mediated binding to platelet glycoprotein Ib. Year Published: 1993
Roon Research Laboratory for Arteriosclerosis and Thrombosis, Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, CA 92037.
29. Expression of human platelet glycoprotein Ib alpha in transgenic mice. Year Published: 1993
Roon Research Center for Arteriosclerosis and Thrombosis, Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.
30. Expression of the phenotypic abnormality of platelet-type von Willebrand disease in a recombinant glycoprotein Ib alpha fragment. Year Published: 1993
Department of Molecular and Experimental Medicine/Committee on Vascular Biology, Roon Research Center for Arteriosclerosis and Thrombosis, Scripps Research Institute, La Jolla, California 92037.
31. von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure. Year Published: 1993
Roon Research Laboratory for Arteriosclerosis and Thrombosis, Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.
32. Point mutation in a leucine-rich repeat of platelet glycoprotein Ib alpha resulting in the Bernard-Soulier syndrome. Year Published: 1993
Roon Research Laboratory for Arteriosclerosis and Thrombosis, Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037.
33. Defective dimerization of von Willebrand factor subunits due to a Cys-> Arg mutation in type IID von Willebrand disease. Year Published: 1996
Universitäts-Kinderklinik, Kiel, Germany.
34. Conformational changes in the A1 domain of von Willebrand factor modulating the interaction with platelet glycoprotein Ibalpha. Year Published: 1996
Roon Research Center for Arteriosclerosis and Thrombosis, Scripps Research Institute, La Jolla, California 92037.
35. Crystal structure of NMC-4 fab anti-von Willebrand factor A1 domain. Year Published: 1997
Roon Research Center for Arteriosclerosis and Thrombosis, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA.
36. A type 2b von Willebrand disease mutation (Ile546-->Val) associated with an unusual phenotype. Year Published: 1998
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital and University of Milano, Italy.
37. Cloning of the murine platelet glycoprotein Ibalpha gene highlighting species-specific platelet adhesion. Year Published: 1997
Roon Research Center for Arteriosclerosis and Thrombosis, Division of Experimental Hemostasis and Thrombosis, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA. jware@scripps.edu
38. Crystal structure of the von Willebrand factor A1 domain in complex with the function blocking NMC-4 Fab. Year Published: 1998
Roon Research Center for Arteriosclerosis and Thrombosis, The Scripps Research Institute, La Jolla, California 92037, USA.
39. Adhesive properties of the isolated amino-terminal domain of platelet glycoprotein Ibalpha in a flow field. Year Published: 1999
Roon Research Center for Arteriosclerosis and Thrombosis, Division of Experimental Hemostasis and Thrombosis, Departments of Molecular and Experimental Medicine, and Vascular Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
40. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Year Published: 2006
CBR Institute for Biomedical Research, Department of Pathology, Harvard Medical School, Boston, MA 02115, USA.
41. Distinct antithrombotic consequences of platelet glycoprotein Ibalpha and VI deficiency in a mouse model of arterial thrombosis. Year Published: 2006
Department of Molecular and Experimental Medicine, Division of Experimental Hemostasis and Thrombosis, The Roon Center for Arteriosclerosis and Thrombosis, The Scripps Research Institute, La Jolla, CA, USA.
42. The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Year Published: 2006
CBR Institute for Biomedical Research and Department of Pathology, Harvard Medical School, Boston, MA 02115, USA. bergmeier@cbrinstitute.org
43. Contribution of leptin receptor N-linked glycans to leptin binding. Year Published: 2008
Roon Research Center for Arteriosclerosis and Thrombosis, Division of Blood Cell and Vascular Biology, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, U.S.A.
44. The Modifier of hemostasis (Mh) locus on chromosome 4 controls in vivo hemostasis of Gp6-/- mice. Year Published: 2008
Roon Research Center for Arteriosclerosis and Thrombosis, Division of Experimental Hemostasis and Thrombosis, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA.
45. Contribution of leptin receptor N-linked glycans to leptin binding. Year Published: 2008
Roon Research Center for Arteriosclerosis and Thrombosis, Division of Blood Cell and Vascular Biology, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA.